Effectiveness of Homoeopathic Medicines in the treatment of non alcoholic fatty liver disease.

Effectiveness of Individualized Homoeopathic Medicine in comparison with Chionanthus Virginica 6C in the treatment of non alcoholic fatty liver disease an open label randomized clinical trial. - NIL

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/02/080994

Enrollment

Registered

2025-02-20

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

Intervention1: Individualized Homoeopathic medicine in case of non alcoholic fatty liver disease: Individualized Homoeopathic medicine in case of non alcoholic fatty liver disease evaluated by Liver f

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed cases of fatty liver of any grade as visible in USG Patient with elevated liver enzyme ALT more than 40 international unit per liter in Blood Both male and female patients aged between 20 to 70 years irrespective of all religions, and of different socioeconomic status who are willing to give written consent for participating in study and complete follow-up during study NAFLD confirmed by USG with or without having symptoms like fatigue, mild discomfort in the upper quadrant of abdomen who are willing to give written consent for participating in the study and complete follow up during study

Exclusion criteria

Exclusion criteria: Pregnant females and lactating mothers. Individuals not providing written informed consent for the study. Patient with evidence of liver disease other than NAFLD like alcoholic fatty liver, viral hepatitis, autoimmune liver diseases, hepatocellular carcinoma, Gilbert syndrome, Crigler Najjar syndrome, Wilson disease, Hemochromatosis etc. Patient with uncontrolled diabetes, uncontrolled hypertension, renal or cardiac disease, stroke or any other serious systemic and terminal illness. Patient who are taking any allopathic medicine or supplementary medicine for NAFLD. There is history of significant alcohol consumption.

Design outcomes

Primary

Measure	Time frame
Changes in LFT parameters ALT, AST, ALP, GGT, Bilirubin, Albumin, Globulin will be assessed.Timepoint: Changes in LFT parameters ALT, AST, ALP, GGT, Bilirubin, Albumin, Globulin will be assessed at baseline, 3 months and 6 months.	—

Secondary

Measure	Time frame
Changes in USG will be assessed. Changes in BARD SCORE will be assessed. Timepoint: baseline and 6 months.	—

Countries

India

Contacts

Public ContactDr Usha Ghelani Uchat

National Institute of Homoeopathy

souvikpoali@gmail.com7384334915

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026